Vimta Labs Limited Reports Q4 & Fy26 Results With 19.5% Yoy Revenue Growth

Vimta Labs Limited (VIMTA) announced its financial results for the quarter and year ended March 31, 2026, showcasing a robust performance. The company reported a total income of Rs. 1,120 Mn for Q4 FY26, marking a 11.5% year-over-year (YoY) increase. On a full-year basis, Vimta Labs achieved a total income of Rs. 4,163 Mn, up by 19.5% YoY. The exceptional performance was driven by the Pharma and Food divisions.

Financial Highlights

The EBITDA for Q4 FY26 was Rs. 421 Mn, with an EBITDA margin of 37.6%. For the full year, the EBITDA stood at Rs. 1,489 Mn, maintaining an EBITDA margin of 35.8%. The PAT for Q4 FY26 was Rs. 211 Mn, and for FY26, it was Rs. 775 Mn. The PAT margin for Q4 FY26 was 18.9%, and for FY26, it was 18.6%.

Strategic Moves

Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies in August 2024, enhancing its focus on core competencies. The company remains committed to expanding capabilities, investing in technology, and strengthening long-term partnerships to drive sustainable growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Vimta Labs Limited

Vimta Labs Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Vimta rises 10.4% over three months, with buying pressure holding steady. The PEG of 1.61 limits the upside. The stock does not come cheap. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock sits at 22% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. The stock rises 10.4% in three months on 7.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Vimta Labs Limited.